Biogen manufactures onsite Avonex and Tysabri, both indicated for multiple sclerosis (MS), as well as a number of other clinical products. The 300-person Patient Services group serves MS patients and their caregivers.
“With the opening of this beautiful facility Biogen Idec has united on one site more than 1,000 people dedicated to meeting the needs of patients with serious diseases,” said George A. Scangos, Ph.D., chief executive officer of Biogen Idec. “The expansion of our footprint in RTP underscores our commitment to providing a secure supply of medicines and to helping patients overcome obstacles to receiving them.”
“Our RTP site focuses on patient care — from manufacturing high quality therapies to providing patient support and financial assistance. With this new building, our employees are constantly reminded of our purpose through the patient stories that adorn the main areas and workspaces within the building,” said Machelle Sanders, vice president of manufacturing and general manager for Biogen Idec RTP.